BioSante Expects Estradiol, Testosterone Gel Filings In 2004; Marketing Will Ride Solvay Coattails
This article was originally published in The Pink Sheet Daily
Executive Summary
Company aims to capture 10%-20% of the testosterone gel market with Bio-T-Gel. Female sexual dysfunction will be next frontier for BioSante gels, with Procter & Gamble as trailblazer in FSD market, BioSante CEO says.
You may also be interested in...
Indevus Plans End-Of-Summer NDA For Nebido Following Positive Phase III Results
Specialty pharma will price the quarterly injectable hypogonadism therapy to compete with current topical treatments.
Indevus Plans End-Of-Summer NDA For Nebido Following Positive Phase III Results
Specialty pharma will price the quarterly injectable hypogonadism therapy to compete with current topical treatments.
BioSante Bio-E-Gel Transdermal Estradiol Is Firm’s First NDA
BioSante is seeking approval of Bio-E-Gel for treatment of moderate-to-severe hot flashes in menopausal women.